shares of Kala Pharmaceuticals Inc (KALA) on
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 130 full-time employees. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The firm has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient’s eye, often at monthly intervals.